已收盘 11-08 16:00:00 美东时间
0.000
0.00%
Can-Fite BioPharma's VP of Business Development, Dr. Sari Fishman, will present updates on the Phase IIa study of Namodenoson for advanced pancreatic cancer at the BIO 2025 Convention. The trial, led by Prof. Salomon Stemmer, has enrolled 50% of its target patients and shown a favorable safety profile.
2025-06-16 13:00